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Abstract: In a search of small molecules active against apoptosis-resistant cancer cells, including 
glioma, melanoma, and non-small cell lung cancer, we previously prepared α,β- and γ,δ-unsatu-
rated ester analogues of polygodial and ophiobolin A, compounds capable of pyrrolylation of pri-
mary amines and demonstrating double-digit micromolar antiproliferative potencies in cancer cells. 
In the current work, we synthesized dimeric and trimeric variants of such compounds in an effort 
to discover compounds that could crosslink biological primary amine containing targets. We 
showed that such compounds retain the pyrrolylation ability and possess enhanced single-digit mi-
cromolar potencies toward apoptosis-resistant cancer cells. Target identification studies of these in-
teresting compounds are underway. 
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1. Introduction 
Cancers with intrinsic resistance to apoptosis are characterized by the lack of respon-
siveness to the current chemotherapeutic agents that generally work by the induction of 
apoptosis in cancer cells. These cancers include tumors of the lung, melanoma and glio-
blastoma and they represent a major challenge in the clinic [1]. For example, patients af-
flicted by glioblastoma multiforme [2,3], have a median survival expectancy of less than 
14 months when treated with the best available protocol that involves surgery, radiation 
and chemotherapy with temozolomide [4]. Further, the main cause of death of cancer pa-
tients are tumor metastases. Metastatic cells are resistant to anoikis, a type of apoptotic 
cell death triggered by the loss of contact with the extracellular matrix or neighboring cells 
[5]. Resistance to anoikis, and thus apoptosis, renders metastatic cells unresponsive to the 
large majority of proapoptotic agents as well [3,6]. Therefore, a search for novel anticancer 
agents that can overcome cancer cell resistance, including resistance to apoptosis, is an 
important pursuit. 
In this connection, natural products represent a valuable source of not only cytotoxic 
compounds, but also those capable of overcoming the intrinsic resistance of cancer cells 
to apoptosis [7–10]. Half of the anticancer drugs developed since the 1940s either origi-
nated from natural sources, such as vinca alkaloids, taxanes, podophyllotoxin, and camp-
tothecins; or synthetic derivatization of natural products, such as vinflunine (fluorinated 
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vinca alkaloid derivative), cabazitaxel (derivative of a natural taxoid), and mifamurtide 
(derivative of muramyl dipeptide) [11,12]. 
In addition to their ability to infiltrate a variety of cell processes and locales, natural 
products are known to be able to modulate multiple molecular targets that are frequently 
deregulated in cancers. This can be especially useful for overcoming the resistance of can-
cer cells to single-target pharmaceutical drugs [13,14]. While apoptosis is the most wide-
spread and well-studied mode of cell death induced by synthetic and naturally occurring 
anticancer agents, alternative mechanisms of cell death (including, autophagy, regulated 
necrosis, mitotic catastrophe, paraptosis, parthanatos, methuosis, and lysosomal mem-
brane permeabilization) are prevalent among natural products [15–17]. 
In the pursuit of agents active against apoptosis- and multidrug-resistant cancer cells, 
our recent studies have focused on the synthetic derivatives of polygodial (Figure 1a), a 
sesquiterpenoid dialdehyde isolated from Tasmannia lanceolata, and ophiobolin A (Figure 
1b), a plant toxin isolated from pathogenic fungi of the Bipolaris genus (Drechslera gigantea 
and Bipolaris maydis). For instance, we have shown that C12-Wittig derivatives of polygo-
dial (1) exhibit antiproliferative activity mainly through cytostatic effects and in many 
cases display higher efficiency compared to the parent compound [18]. Additionally, both 
polygodial and compound 1 can readily undergo the pyrrole formation with primary 
amines to give 3 and 2, which can lead to pyrrolation of lysine residues in biological envi-
ronment [18–20]. 
 
Figure 1. (a) Structures of polygodial, Wittig product 1, a proposed mechanism for pyrrole 2 formation involving interme-
diates I and II, unstable pyrrole 3; (b) Structures of ophiobolin A, Wittig product 4, pyrrole 5 and conjugated phosphati-
dylethanolamine 6. 
Another natural anticancer product, ophiobolin A (Figure 1b), represents an interest-
ing candidate for the treatment of apoptosis-resistant cancer cells due to a unique mecha-
nism of action [21]. It was demonstrated to induce paraptosis in glioblastoma cells, offer-
ing an innovative strategy to combat this aggressive cancer. This cellular effect is under-
stood to also originate from pyrrolylation of primary amine groups abundant in human 
cells (5) [22], such as intracellular lysine residues or phosphatidylethanolamine (6), which 
would lead to lipid bilayer destabilization [23]. Similarly to polygodial derivative 1, oph-
iobolin A can be converted into α,β-unsaturated ester 4 when treated with stabilized Wit-
tig reagents [22]. 
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The work reported in the current manuscript describes the early attempts of improv-
ing anticancer activity of polygodial and ophiobolin A derivatives through preparation of 
synthetic analogues that are capable of the covalent crosslinking of anticancer targets via 
the pyrrolylation of primary amines. The method that we envisioned involves the con-
struction of dimeric conjugates of above-mentioned natural products. This approach has 
a proven record of success in oncology: such dimeric conjugates were often found to pos-
sess significantly improved anticancer activity compared to parent compounds (Figure 2) 
[24–31]. 
 
Figure 2. Dimeric anticancer conjugates of natural products: (a) Melampomagnolide B, its monomeric (8) and dimeric (7) 
derivatives; (b) Anthramycin, dimer SJG-136 and schematic representation of interstrand cross-link formation through 
DNA binding. 
For instance, Crooks and coworkers [24] synthesized dimers of anticancer sesquiter-
pene lactone melampomagnolide B (Figure 2a) and assessed their activity against the NCI 
panel of 60 human hematological and solid tumor cell lines. Most active products exhib-
ited potent growth inhibition (GI50 = 0.16–0.99 μM) against the majority of cells. Notably, 
some of the compounds (7) displayed up to 1 × 106-fold higher cytotoxic effect against rat 
9L-SF gliosarcoma cells when compared to previously developed monomeric 
melampomagnolide B analogs, such as DMAPT (8). This remarkable increase in activity 
for dimeric structures was attributed to the ability to provide multiple covalent interaction 
opportunities with multiple exposed surface cysteine residues of the GCLC and GCLM 
proteins via the formation of Michael addition adducts. 
Another well-known example of rationally designed anticancer dimers involves the 
synthetic modification of the naturally occurring pyrrolobenzodiazepine (PBD) antitumor 
antibiotics, such as Anthramycin (Figure 2b) [25,26]. These compounds are sequence-se-
lective DNA minor-groove binding agents. When monomeric PBD units were linked to 
form dimers containing two alkylating imine functionalities, it allowed them to form in-
terstrand or intrastrand DNA cross-links in addition to mono-alkylated adducts, thus re-
sulting in significantly greater cytotoxicity, antitumor activity and antibacterial activity 
compared to PBD monomers due to the different mode of DNA damage (Figure 2b) [25]. 
One of these dimers, SJG-136, has displayed potent cytotoxicity in the low nM range 
against human tumor cell lines and reached Phase II clinical trials in ovarian cancer and 
leukemia. Subsequent structural modification of the PBD dimers resulted in compounds 
with enhanced potency through increased interstrand DNA cross-linking ability, includ-
ing agents with pM and in some cases sub-pM, activity in vitro [26]. These compounds 
were also employed as chemical payloads of antibody–drug conjugates, some of which 
are now in Phase III clinical trials [31]. 
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2. Results and Discussion 
In order to reduce the concept of multivalent anticancer conjugates to practice, in this 
work we focused on the preparation and assessment of dimeric polygodial and ophiobo-
lin A α,β-unsaturated esters [32,33]. The synthesis of polygodial esters was initiated by 
the preparation of bromoacetates 9, 10 and 11 with varied ethylene glycol chain lengths 
by heating diethylene, triethylene and tetraethylene glycols with bromoacetic acid under 
neat conditions (Figure 3). Bromoacetates 9, 10 and 11 were then reacted with 2 eq of tri-
phenylphosphine in toluene at room temperature to give phosphonium bromides 12, 13 
and 14, respectively, which were conveniently purified with column chromatography on 
silica gel. Finally, the latter were subjected to Wittig olefination with polygodial, to yield 
dimeric α,β- and γ,δ-unsaturated esters 15, 16 and 17 with varied linker chain lengths 
based on the number of incorporated ethylene glycol moieties. In a manner similar to the 
preparation of monomeric α,β- and γ,δ-unsaturated esters, such as 1 [18], polygodial re-
acted at the C-12 aldehyde only, possibly due to the sterically congested nature of the C-
11 aldehyde group. 
To confirm that the dimeric unsaturated esters retain the pyrrole forming ability 
upon the reaction with primary amines such as lysine residues in proteins, compound 15 
was reacted with benzyl amine in the presence of AcOH in THF at room temperature and 
bis-pyrrole 18 was isolated in 70% yield (Figure 4). We also explored the preparation of a 
possible trimeric unsaturated ester. To this end, glycerol was reacted with bromoacetic 
acid under neat conditions to give tribromoacetate 19. The latter was then subjected to a 
reaction with 3 eq of triphenylphosphine and phosphonium bromide 20 was isolated and 
purified with column chromatography on silica gel. The latter was treated with 3 eq of 
polygodial in the presence of Et3N in THF at room temperature to give the desired trimeric 
α,β- and γ,δ-unsaturated ester 21 (Figure 5). 
Ophiobolin A α,β- and γ,δ-unsaturated ester dimers 22 and 23, containing one and 
two ethylene glycol unit linkers, respectively, were synthesized using bis(tri-
phenylphosphonium) bromides 12 and 13 (Figure 6). The latter were stirred with excess 
of ophiobolin A in the presence of Et3N in THF at room temperature for 48 h and yielded 
the desired dimers in good yields. 
 
Figure 3. Synthesis of dimeric polygodial-based crosslinking agents 15, 16 and 17. 
 
Figure 4. Demonstration of the feasibility of the formation of bis-pyrrole 18 from dimer 15. 




Figure 5. Synthesis of trimeric polygodial-based crosslinking agent 21. 
 
Figure 6. Synthesis of ophiobolin A-based crosslinking agents 22 and 23. 
The synthesized polygodial and ophiobolin A dimeric and trimeric unsaturated es-
ters were evaluated for in vitro growth inhibition using the MTT colorimetric assay 
against a panel of six cancer cell lines. This included cells resistant to a number pro-apop-
totic stimuli, such as human A549 non-small cell lung cancer (NSCLC) [34], human glio-
blastoma U373 [35,36], and human SKMEL-28 melanoma [37], as well as tumor models, 
which are largely susceptible to apoptosis-inducing stimuli, such as human Hs683 ana-
plastic oligodendroglioma [36], human MCF-7 breast adenocarcinoma [38] and mouse 
B16F10 melanoma (Table 1) [37]. Analysis of these data reveals that where monomeric 
α,β- and γ,δ-unsaturated esters of polygodial (1) and ophiobolin A (4) possess double 
digit micromolar antiproliferative potencies, dimeric polygodial unsaturated ester with 
one ethylene glycol linker 15 and both ophiobolin unsaturated esters 22 and 23 have single 
digit micromolar potencies. Thus, the conversion of monomeric covalently reacting 
polygodial and ophiobolin A unsaturated esters into their dimeric analogues is capable of 
enhancing the potency by an order of magnitude. Such potencies compare favorably with 
the clinically used cancer drug cisplatin (Table 1). It is noteworthy that the lengthening of 
the ethylene glycol linker between the polygodial molecules to two and to three units, i.e., 
15→16→17, progressively leads to a decrease in the potency of the dimers, pointing to a 
possible specificity of the interaction between these dimeric agents and their intracellular 
targets. This specificity is likely to be lost with the trimeric agent 21, where the potency is 
in double digit micromolar region as well. Our data are similar to what has been seen in 
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investigations of linker lengths in dimeric agents targeting G protein-coupled receptors 
[39], estrogen receptors [40], proteolysis targeting chimeras [39], among others [41].  
Table 1. In vitro growth inhibitory effects of cross-linking agents in comparison with their mono-
meric counterparts. 
Compound 
GI50 In Vitro Values (µM) 1 
Resistant to Apoptosis Sensitive to Apoptosis 
A549 SKMEL-28 U373 MCF7 Hs683 B16F10 
1 30 42 41 36 29 7 
15 7 14 9 4 4 5 
16 17 22 28 9 8 9 
17 55 29 79 36 50 24 
21 25 24 28 23 17 6 
4 2 59 86 86 43 59 ND 
22 5 8 32 8 10 4 
23 4 3 5 3 3 3 
cisplatin 7 26 ND 35 7 8 
1 Mean concentration required to reduce the viability of cells by 50% after a 72 h treatment relative 
to a control, each experiment performed in sextuplicates, as determined by MTT assay. 2 Data are 
from ref. [22]. ND = not determined. 
It is noteworthy that polygodial and ophiobolin A unsaturated esters displayed com-
parable potencies in cells both sensitive and resistant to apoptosis induction, indicating 
that this family of compounds is capable of overcoming apoptosis resistance in the clinic 
(Table 1) [18,22]. The comparison of the cellular effects of monomeric (1 and 4) and dimeric 
(15 and 23) polygodial and ophiobolin A esters on human glioblastoma U373 cells by 
phase contrast videomicroscopy did not reveal marked changes between the monomers 
and their respective dimers at their respective GI50 concentrations (Figure 7). Phenotypi-
cally, it thus appears that the mode of action has not changed with the dimerization, de-
spite the increase in potency. 




Figure 7. In vitro videomicroscopic analysis of the anticancer effects of monomeric Wittig products 1 and 4 as well as 
cross-linking agents 15 and 23. The U373 human glioma cell line was treated with polygodial and ophiobolin A derivatives 
at their mean GI50 concentrations (Table 1) or left untreated. The experiment was conducted once in triplicate. Scale bars 
correspond to 100 μm. 
3. Materials and Methods 
3.1. Human Cell Lines and Antiproliferative Effects 
Breast carcinoma MCF-7 (DSMZ ACC107), oligodendroglioma Hs683 (ATCC 
HTB138), non-small cell lung cancer A549 (DSMZ ACC107), glioblastoma U373 (ECACC 
08061901), melanoma SKMEL-28 (ATCC HTB72) and the murine melanoma B16F10 
(ATCC CRL-6475) were cultured in RPMI supplemented with 10% heat-inactivated FBS 
(GIBCO code 10270106), 4 mM glutamine (Lonza code BE17-605E), 100 μg/mL gentamicin 
(Lonza code 17-5182), and penicillin-streptomycin (200 units/mL and 200 μg/mL) (Lonza 
code 17-602E). Cell lines were cultured in flasks, maintained and grown at 37 °C, 95% 
humidity, 5% CO2. Antiproliferative effects of the compounds on these cell lines were 
evaluated through the colorimetric assay MTT. Briefly, cells were trypsinized and seeded 
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in 96-well plates. Prior to treatment, compounds were dissolved in DMSO at a concentra-
tion of 10 mM. After 24 h, cells were treated with the compounds at different concentra-
tions ranging from 10 nM to 100 μM or left untreated for 72 h. Cell viability was estimated 
by means of the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, 
Sigma, Bornem, Belgium) mitochondrial reduction into formazan in living cells. The opti-
cal density of the untreated control was normalized as 100% of viable cells, allowing de-
termination of the concentration that reduced their global growth by 50%. 
3.2. Natural Product Isolation 
Polygodial was isolated from Tasmannia lanceolata following a reported procedure 
[32]. 
Ophiobolin A was isolated from Drechslera gigantea following a reported procedure 
[33]. 
3.3. Selected Procedure for the Preparation of Polygodial-Based Cross-Linking Agent 16 
To a solution of Wittig salt 13 (17.5 mg, 0.02 mmol) in THF (2 mL) was added triethyl-
amine (18 μL, 0.13 mmol). The reaction was stirred for 20 min until the Wittig salt dis-
solved. A solution of polygodial (32.9 mg, 0.14 mmol) was dissolved in THF (0.5 mL) sep-
arately and added dropwise to the reaction mixture. The reaction mixture was stirred for 
48 h and monitored by TLC (20% ethyl acetate/hexane). The reaction mixture was concen-
trated and purified by preparative TLC to yield 8.8 mg of 16 (70%). 1H NMR (400 MHz, 
CDCl3) δ 9.48 (d, J = 4.7 Hz, 2H), 7.33 (d, J = 10.6 Hz, 2H), 6.52 (dd, J = 8.6, 5.3 Hz, 2H), 5.53 
(d, J = 16.3 Hz, 2H), 4.36–4.17 (m, 4H), 3.73–3.67 (m, 4H), 2.91–0.81 (m, 38H). 13C NMR (500 
MHz, CDCl3) δ 205.6 (2C), 167.4 (2C), 147.4 (2C), 142.2 (2C), 130.9 (2C), 116.6 (2C), 69.6 
(2C), 64.0 (2C), 63.2 (2C), 49.1 (2C), 42.2 (2C), 40.7 (2C), 37.9 (2C), 33.7 (2C), 33.6 (2C), 25.4 
(2C), 22.7 (2C), 18.5 (2C), 16.0 (2C). HRMS m/z (ESI) calcd for C38H54O7Na (M+Na) 
645.3767, found 645.3769. 
3.4. Selected Procedure for the Preparation of Ophiobolin A-Based Cross-Linking Agent 23 
To a solution of Wittig salt 13 (3.1 mg, 3.6 μmol) in THF (2 mL) was added triethyla-
mine (3.2 μL, 0.023 mmol). The reaction was stirred for 20 min until the Wittig salt dis-
solved. A solution of OpA (10 mg, 0.025 mmol) was dissolved in THF (1 mL) separately 
and added dropwise to the reaction mixture. The reaction mixture was stirred for 48 h and 
monitored by TLC (20% ethyl acetate/hexane). The reaction mixture was concentrated and 
purified by preparative TLC to yield 2.8 mg of 23 (82%). 1H NMR (400 MHz, MeOD) δ 7.32 
(dd, J = 15.6, 0.7 Hz, 2H), 6.43 (t, J = 8.5 Hz, 2H), 5.97 (d, J = 15.6 Hz, 2H), 5.23–5.16 (m, 2H), 
4.55–4.45 (m, 2H), 4.27–4.18 (m, 4H), 3.75–3.69 (m, 4H), 3.67–3.62 (m, 2H), 3.60–3.55 (m, 
2H), 2.58–2.45 (m, 4H), 2.45–2.36 (m, 2H), 2.25–2.21 (m, 2H), 2.19–2.06 (m, 6H), 1.87–1.77 
(m, 2H), 1.74 (d, J = 1.2 Hz, 6H), 1.70 (d, J = 1.2 Hz, 6H), 1.67–1.63 (m, 2H), 1.62–1.39 (m, 
8H), 1.37 (s, 6H), 1.33–1.26 (m, 2H), 1.09 (d, J = 7.2 Hz, 6H), 0.97–0.89 (m, 2H), 0.88 (s, 6H). 
13C NMR (100 MHz, MeOD) δ 167.3 (2C), 148.1 (2C), 137.1 (2C), 135.4 (2C), 133.6 (2C), 125.5 
(2C), 115.9 (2C), 95.3 (2C), 77.1 (2C), 71.1 (2C), 68.9 (2C), 63.3 (2C), 61.3 (2C), 59.9 (2C), 54.5 
(2C), 51.6 (2C), 50.3 (2C), 42.7 (2C), 42.6 (2C), 40.7 (2C), 36.5 (2C), 34.8 (2C), 30.1 (2C), 24.6 
(2C), 24.1 (2C), 22.1 (2C), 17.0 (2C), 16.9 (2C), 16.8 (2C). HRMS m/z (ESI) calcd for 
C58H82O11Na (M+Na) 977.5749, found 977.5164. 
4. Conclusions 
In conclusion, previously we synthesized α,β- and γ,δ-unsaturated esters of polygo-
dial and ophiobolin A with potential covalent reactivity in cancer cells, i.e., pyrrolylation 
of lysine residues in proteins. In the present work we converted such covalently reacting 
compounds into dimeric and even trimeric species, capable of crosslinking proteins 
through such pyrrolylation reactions. Indeed, we showed that such dimeric compounds 
retain the ability to form pyrroles with primary amines. One selected polygodial dimer 
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with the shortest linker length and both synthesized ophiobolin A dimers possess signif-
icantly enhanced antiproliferative potencies compared with their monomeric analogues, 
supporting this research premise. Mechanistic studies with a possible identification of in-
tracellular targets for these molecules are underway. 
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